Investigating the role of CD71 in preeclampsia
Immunohistochemical Analysis of CD 71 Levels in the Placenta of Preeclamptic and Normotensive Pregnancies and Comparison With Neonatal Outcomes
This study is trying to see if levels of certain markers in the placenta can help us understand why some pregnant women develop preeclampsia compared to those with normal blood pressure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 39 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Celal Bayar University Academic / other |
| Locations | 1 site (Manisa, Yunusemre) |
| Trial ID | NCT06668545 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the levels of CD71 and nitric oxide synthase (NOS) in the placentas of pregnant women diagnosed with preeclampsia compared to those with normal blood pressure. By examining these biomarkers, the study seeks to understand the pathogenesis of preeclampsia and its association with placental dysfunction and fetal growth restriction. The research will be conducted at Manisa Celal Bayar University, involving a carefully selected group of participants to ensure accurate results. The findings may provide insights into the mechanisms underlying preeclampsia and its impact on neonatal outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women under 37 weeks of gestation, aged 18-50, who are literate in Turkish and have no additional diseases.
Not a fit: Patients with high-risk pregnancies, multiple pregnancies, or those with certain chronic conditions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of preeclampsia, potentially leading to improved diagnostic and therapeutic strategies for affected pregnancies.
How similar studies have performed: While the specific investigation of CD71 in preeclampsia is novel, related studies have shown promise in understanding placental dysfunction in similar conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy pregnancy under 37 weeks * Age range 18-50 * Being literate in Turkish * Not having any additional disease * Agreeing to participate in the study Exclusion Criteria: * High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.) * Multiple pregnancy * Pregnant women under the age of 18 * Smoking * Medication use (excluding routinely used food supplements during pregnancy) * Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.) * Immunosuppressive use * Presence of active or chronic infection * Presence of active or chronic inflammatory disease * Patients who gave birth at an external center or later chose to withdraw from the study * Patients who did not have any exclusion criteria at the time of Preeclampsi or when blood was drawn for the control group, but who later developed any exclusion criteria. * Premature birth of patients included in the control group
Where this trial is running
Manisa, Yunusemre
- Kemal Sarsmaz — Manisa, Yunusemre, Turkey (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.